NEW ISSUE
State of the Art on ViV-TAVI; Transseptal Punctures; Endovascular Closure and TF-TAVI; Percutaneous PVL Closure: Long-Term Outcomes; and more
October 20, 2021
1. Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 2. Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 3. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands; 4. Department of Interventional Cardiology, Cardiovascular Institute, University Clinic Hospital, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 5. Cardialysis B.V., Rotterdam, the Netherlands; 6. Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland
Introduction
The BuMA Supreme™ (SINOMED, Tianjin, China) is a sirolimus-eluting stent that has a biodegradable PLGA-polymer coating with an electro-grafting base layer on a thin-strut (80 µm) cobalt-chromium platform1. The PIONEER trial is a randomised study assessing the efficacy and safety of the BuMA Supreme compared with the Resolute™ stent (Medtronic, Minneapolis, MN, USA). The primary endpoint was the non-inferiority of the BuMA Supreme in terms of the nine-month angiographic in-stent late lumen loss (LLL). At nine months, the BuMA Supreme had a significantly higher in-stent LLL than the Resolute stent (0.29±0.33 vs 0.14±0.37 mm)1. Nevertheless, ...
Sign in to read and download the full article
Forgot your password?No account yet? Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Coronary interventionsStents and scaffolds
Read next article
Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial